SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: Johnson & Johnson Business Center in Switzerland
Drug Development
J&J Scores Phase III Victory in Major Depressive Disorder
Johnson & Johnson on Wednesday reported late-stage trial data showing its first-in-class orexin receptor antagonist reduced major depressive disorder symptoms as an adjunctive treatment in patients with insomnia.
May 29, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Husband consoles agitated wife/
Drug Development
Otsuka Drops Alzheimer’s Agitation Drug Following Phase III Failure
Otsuka Pharmaceuticals announced Wednesday it is ending development of drug candidate AVP-786 after failing to improve agitation associated with dementia due to Alzheimer’s disease.
May 22, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: A vibrant collage with layered mind and keyhole
Drug Development
Precision Medicine and Novel Approaches on Cusp of Breaking Through in Psychiatry
Approaches and targets for depression and other mental health illnesses have remained stagnant for decades. With several readouts for novel therapies on the horizon, that could be changing.
May 21, 2024
 · 
5 min read
 · 
Kate Goodwin
Pictured: Eli Lilly Campus in San Diego
Business
Lilly Inks Potential $1.1B Radiopharma Deal with Aktis Oncology
Eli Lilly is paying $60 million upfront to Aktis Oncology to discover and develop novel tumor-targeting radiopharmaceuticals, as radiopharma dealmaking continues to heat up in 2024.
May 21, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Nasdaq building in Time Square
Deals
Rapport Therapeutics and Telix Pharma File IPOs as Number of Biotechs Going Public Slows
Neuroscience-focused Rapport Therapeutics and radiopharma developer Telix Pharma announced their respective plans Friday for initial public offerings on the Nasdaq for undisclosed dollar amounts.
May 20, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Pregnant woman sitting in a chair in distress/iStock, Motortion
Policy
EU Regulator Pulls Approval for Preterm Labor Drug One Year After FDA
A European Medicines Agency panel on Friday cited a possible but unconfirmed risk of cancer and recommended that hydroxyprogesterone caproate drugs be suspended from the European Union market.
May 17, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Johnson & Johnson Business Center in Switzerland
Deals
J&J Buys Proteologix for $850M, Bispecific Antibodies for Atopic Dermatitis
Johnson & Johnson announced Thursday it is paying $850 million in cash, plus a potential milestone payment, for privately held biotech Proteologix and its atopic dermatitis-focused bispecific antibody candidates.
May 16, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Photo illustration of hundred dollar bill and graph
Drug Development
Uniquity Bio Emerges from Stealth with $300M from Blackstone, Targets Asthma and COPD
Armed with a $300 million commitment from Blackstone Life Sciences and a former Merck monoclonal antibody, Uniquity Bio is starting Phase II clinical trials in asthma and chronic obstructive pulmonary disease.
May 15, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: The front entrance to the FDA headquarters/iStock, Grandbrothers
Policy
FDA Rejects Dynavax’s Bid to Expand Use of Hepatitis B Vaccine
Dynavax Technologies announced Tuesday that the FDA issued a Complete Response Letter to the company’s sBLA to include a four-dose regimen of Heplisav-B vaccine for adult hemodialysis patients.
May 14, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Merck office building in Canada
Drug Development
Merck Ends Phase III Anti-TIGIT, Keytruda Skin Cancer Study with High Dropouts
A pre-planned analysis revealed patients receiving the vibostolimab-Keytruda coformulation in a late-stage trial had a high rate of dropouts due to immune-related adverse events, Merck announced Monday.
May 13, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Sanofi Distribution Center
Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine
Sanofi will hand Novavax $500 million upfront for its COVID-19 vaccine, which it will co-commercialize and develop into a combination flu-COVID vaccine.
May 10, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Merck building and sign in Silicon Valley
Drug Development
Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop
After a combination with Eisai’s Lenvima failed to improve survival in advanced disease in December, adjuvant Keytruda plus chemotherapy missed the mark in newly diagnosed, high-risk patients.
May 9, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Regeneron headquarters in Tarrytown, N.Y.
Business
Regeneron Misses Q1 Earnings on Lower-Than-Expected Eylea Sales
Regeneron Pharmaceuticals on Thursday reported $1.4 billion in sales of its blockbuster eye drug in the first quarter of 2024, falling short of Wall Street’s expectations of $1.86 billion.
May 2, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: A sign on a J.P. Morgan building in Hong Kong/iStock, danielvfung
Enlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Group
Enlaza Therapeutics on Tuesday announced financing led by the Life Sciences Group of J.P. Morgan Asset Management’s Private Capital division, which the California-based company will use to build its pipeline of covalent biologics.
April 30, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: A collage of injectable drugs, a scale and a BMI chart
Drug Development
What’s Next for Obesity Therapeutics? Higher Quality Weight Loss
With GLP-1 agonists slated to become the best-selling drugs in 2024, the biopharma industry is already pivoting to explore treatments that preserve muscle mass as patients shed pounds.
April 26, 2024
 · 
5 min read
 · 
Kate Goodwin
Load More